Joel W. Neal
- Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
2021/02/25 by Gregory J. Riely, Joel W. Neal, D. Ross Camidge +19 · 1 citation
Medicine · Biochemistry, Genetics and Molecular Biology · #Lung Cancer Treatments and Mutations #PI3K/AKT/mTOR signaling in cancer #Colorectal Cancer Treatments and Studies #Medicine #Rash #Nausea #Lung cancer #Adverse effect #Internal medicine #Vomiting #Diarrhea #Phases of clinical research #Oncology #Mucositis #Clinical trial #Epidermal growth factor receptor #Gastroenterology #Population #Toxicity #Cancer